Market Overview

UBS Downgrades InterMune To Neutral

Related ITMN
What You Need to Know About the Roche-InterMune Deal
Markets Reverse Early Morning Losses; Still Lower On The Day

Analysts at UBS downgraded InterMune (NASDAQ: ITMN) from Buy to Neutral.

The price target for InterMune has been raised from $52.00 to $74.00.

InterMune shares have jumped 403.30% over the past 52 weeks, while the S&P 500 index has gained 22.33% in the same period.

InterMune shares rose 0.01% to $73.18 at 10:40 a.m. ET.

Latest Ratings for ITMN

Aug 2014UBSDowngradesBuyNeutral
Aug 2014Cowen & Co.Initiates Coverage onMarket Perform
Aug 2014JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ITMN
View the Latest Analyst Ratings

Posted-In: UBSDowngrades Analyst Ratings


Related Articles (ITMN)

View Comments and Join the Discussion!

Partner Center